Table 2.
At 6 months | ||||
---|---|---|---|---|
LSC 95% | ABL-SC 80 μg | TPTD | Placebo | |
Significant individual gain (%) | + 4.20 | 52.2* | 30.0‡ | 10.3 |
Significant individual loss (%) | − 4.20 | 0.0¥ | 6.7 | 17.2 |
ABL-SC abaloparatide-SC, LSC least significant change, TPTD teriparatide
*p = 0.001 versus placebo
‡ p = 0.06 versus placebo
¥ p = 0.05 versus placebo